PreEvnt announced today that its Isaac non-invasive glucose monitoring system has entered clinical trials. Under the direction of Dr. Mangilal Agarwal, the device entered trials at Indiana University, Indianapolis. The study marks a step forward … [Read More...] about PreEvnt brings non-invasive glucose alert device to clinical trials
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
Insulet wins FDA clearance for Omnipod 5 algorithm enhancements
Insulet (Nasdaq:PODD) announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system. The Acton, Massachusetts–based company said the updates to its tubeless, wearable automated insulin delivery patch pump's … [Read More...] about Insulet wins FDA clearance for Omnipod 5 algorithm enhancements
Insulet makes Omnipod 5 available with Dexcom G7 15 Day CGM
Insulet (Nasdaq:PODD) today announced immediate compatibility between its Omnipod 5 system and the Dexcom (Nasdaq:DXCM) G7 15 Day CGM. Acton, Massachusetts-based Insulet, which has paired its pumps with previous versions of Dexcom continuous … [Read More...] about Insulet makes Omnipod 5 available with Dexcom G7 15 Day CGM
Medtronic begins full commercial rollout of MiniMed 780G with Instinct sensor made by Abbott
Medtronic (NYSE:MDT) today announced the full U.S. launch for its Instinct sensor, made by Abbott, paired with the MiniMed 780G pump. The medtech giant’s diabetes unit — one of the largest diabetes tech businesses in the world — won FDA clearance … [Read More...] about Medtronic begins full commercial rollout of MiniMed 780G with Instinct sensor made by Abbott
Embecta Q4 sales fall short amid dynamic market, China hurdles
Embecta (Nasdaq:EMBC) today posted fourth-quarter financial results that proved mixed compared to the consensus forecast on Wall Street. Shares of EMBC remained unmoved at $14.64 apiece in pre-market trading today. The Parsippany, New Jersey-based … [Read More...] about Embecta Q4 sales fall short amid dynamic market, China hurdles
PreEvnt brings non-invasive glucose alert device to clinical trials
PreEvnt announced today that its Isaac non-invasive glucose monitoring system has entered clinical trials. Under the direction of Dr. Mangilal Agarwal, the device entered trials at Indiana University, Indianapolis. The study marks a step forward … [Read More...] about PreEvnt brings non-invasive glucose alert device to clinical trials
Abbott initiates correction for FreeStyle Libre 3, Libre 3 Plus CGMs after reports of deaths
Abbott (NYSE:ABT) announced today that it issued a medical device correction for certain FreeStyle Libre 3 and Libre 3 Plus sensors in the U.S. This correction comes as a result of an issue that led to hundreds of severe adverse events, including … [Read More...] about Abbott initiates correction for FreeStyle Libre 3, Libre 3 Plus CGMs after reports of deaths
Insulet CEO Ashley McEvoy lays out plans for Omnipod 6, innovation roadmap
Insulet (Nasdaq:PODD) today hosted its Investor Day, led by President and CEO Ashley McEvoy, laying out the future for the insulin pump maker. McEvoy, who assumed the corner office six months ago, has recently spoken about the company's use of … [Read More...] about Insulet CEO Ashley McEvoy lays out plans for Omnipod 6, innovation roadmap
Insulet to launch next-gen Omnipod 6 in 2027, outlines plans for fully closed loop pump for type 2
Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system. At the company's Investor Day event, held at its Acton, Massachusetts headquarters, President and CEO Ashley McEvoy laid … [Read More...] about Insulet to launch next-gen Omnipod 6 in 2027, outlines plans for fully closed loop pump for type 2
Dexcom to launch G7 15 Day CGM next month
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next month. The San Diego–based company plans to make the CGM available for people over the age of 18 with diabetes on Dec. 1. … [Read More...] about Dexcom to launch G7 15 Day CGM next month
Dexcom wins FDA nod for smart CGM-integrated basal dosing for type 2 diabetes
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer. The continuous glucose monitor (CGM)-based offering received clearance for adults with type 2 diabetes on glargine U-100 … [Read More...] about Dexcom wins FDA nod for smart CGM-integrated basal dosing for type 2 diabetes
In case you missed it
- Modular Medical submits next-gen insulin pump to FDA, expects 2026 launch
- Medtronic Diabetes to submit patch pump to FDA by fall 2026, separation remains on track
- 1nhaler raises $2M for cardboard inhaler device
- What diabetes tech companies are doing on World Diabetes Day 2025
- Dexcom unveils new advocates to support World Diabetes Day campaign
- Renu MedTech introduces tubeless insulin patch pump in India
- ViCentra highlights diabetes in the workplace on World Diabetes Day
- Glucotrack now expects spring 2026 FDA IDE submission for implantable CGM
- Carrot, Oura, Dexcom partner on biosensor insights for fertility
- Vivani to initiate study of semaglutide implant in 2026
- What the launch of Mobi for Android means for Tandem, people with diabetes
- Go-Pen wins CE mark for user-fillable insulin pen
- Tandem wins FDA nod to pair Mobi pump with Android smartphones
- The top CGM stories of 2025
- Billie Jean King supports Medtronic Diabetes awareness initiative
Clinical Trials
PreEvnt brings non-invasive glucose alert device to clinical trials
PreEvnt announced today that its Isaac non-invasive glucose monitoring system has entered clinical trials. Under the direction of Dr. Mangilal Agarwal, the device entered trials at Indiana University, Indianapolis. The study marks a step forward in validating Isaac’s potential as a tool for managing diabetes through breath-based measurements. The current phase of research includes adolescents […]
Modular Medical submits next-gen insulin pump to FDA, expects 2026 launch
Modular Medical (Nasdaq:MODD) announced that it has submitted its next-generation Pivot insulin pump to the FDA for clearance. Modular Medical’s current pump, the MODD1, won FDA clearance nearly a year ago. It has microfluidics technology that allows for the low-cost pumping of insulin. The company announced earlier this year that it began converting its manufacturing line to […]
Vivani to initiate study of semaglutide implant in 2026
Vivani Medical (Nasdaq:VANI) today announced third-quarter earnings results that included timeline updates on its semaglutide implant. The Alameda, California-based company develops NanoPortal technology, which steadily delivers medication over extended periods of time. Vivani aims to guarantee correct patient doses while avoiding potential safety concerns around fluctuating drug release profiles. It can also deliver large hydrophilic […]
Tidepool, Oura partner on data for diabetes research
Tidepool today announced a strategic collaboration with Oura to support a groundbreaking dataset for diabetes research. The initiative between the diabetes software developer and smart ring maker aims to create a comprehensive, multi-modal, real-world dataset for diabetes, utilizing Tidepool’s diabetes device data paired with biometric data collected by the leading Oura Ring Gen 3. This […]
Boston Scientific shares positive Agent drug-coated balloon findings
Boston Scientific (NYSE: BSX) today shared findings from new analyses of its Agent drug-coated balloon (DCB). Agent serves as an alternative to traditional therapies like balloon angioplasty, additional layers of stenting or radiation. The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent in-stent restenosis (ISR) reoccurrence. The FDA […]
